302 results
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
14 Aug 23
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
in Japan under the accelerated regulatory pathway applicable to regenerative medicines CD34+ cell therapy current clinical trials Legacy development
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
9 May 23
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:08pm
the accelerated regulatory pathway applicable to regenerative medicines CD34+ cell therapy current clinical trials Legacy development programs provide potential
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
9 May 23
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:08pm
of diabetic kidney disease (“DKD”)
The Company initiated a Phase 1b, open-label, proof-of-concept trial evaluating LSTA201, a CD34+ regenerative cell
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
30 Mar 23
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:07pm
is an experimental regenerative therapy for the treatment of CMD. It was the subject of a positive Phase 2a study (the “ESCaPE-CMD trial”) reported … 1b, open-label, proof-of-concept trial evaluating LSTA201, a CD34+ regenerative cell therapy investigational product for intra-renal artery
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
30 Mar 23
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:07pm
) Designed in conjunction with Japanese regulatory authorities (PDMA) under regenerative medicine regulations Conditional approval can be based … applicable to regenerative medicines CD34+ cell therapy current clinical trials Legacy development programs provide potential value upside with no further
8-K
EX-99.2
pv34jzarddrog33np15
10 Nov 22
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
v4ikrz0iqvon0
10 Nov 22
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
ib5dcpk7 76roc7
22 Sep 22
Regulation FD Disclosure
4:02pm
8-K
EX-99.2
1j0bs5i839mz
15 Sep 22
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
9:16am
8-K
EX-10.1
141 2f3bv
15 Sep 22
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
9:16am
8-K
EX-99.2
hzmuw
5 Aug 22
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
4:01pm
8-K
EX-99.1
9km bhvhy3t5yp3
5 Aug 22
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
4:01pm
8-K
EX-99.3
fnn l4jqj
5 Aug 22
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
4:01pm
424B3
j7x5c3uhz2
29 Jul 22
Prospectus supplement
4:06pm
8-K
EX-99.2
j08y4
23 May 22
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
4:08pm